Products
Akeso, Inc.'s Bispecific Antibody Targeting Aß and BBB-Expressed Receptor Approved for Alzheimer's Disease Clinical Trials in China
Pattern Observed
•Source: MarketScreener
•
•
1 min read
Akeso, Inc. announced that its AK152, a novel bispecific antibody targeting both amyloid-beta (Aß) and blood-brain barrier (BBB) expressed receptor, has been granted approval by the National Medical Products Administration (NMPA) to initiate clinical... [1781 chars]
Article Stats
7 Views
|
Updated 2 days ago
Continue Reading
Products
Beyond the Sparkle: How Sequin Trousers Became a Wardrobe Staple
5 min read
Products
The Quiet Rebellion: How Understated Brands Are Redefining Consumer Desire
5 min read
Products
Fuelling the future: Why India needs maritime muscle as its oil thirst grows
1 min read
Products
Subscription Box Strategy & Consumer Psychology
5 min read
Discussion